A Randomized, Double-Blind, Placebo-Controlled Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity
Latest Information Update: 27 Nov 2025
At a glance
- Drugs RN 3161 (Primary) ; Tirzepatide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Ikaria Bioscience
Most Recent Events
- 24 Nov 2025 Status changed from not yet recruiting to recruiting.
- 10 Nov 2025 New trial record
- 15 Sep 2025 According to a Rona Therapeutics media release, company filed an IND application of RN 3161 to the Australian Human Research Ethics Committee (HREC) and intends to initiate a clinical trial for the treatment of obesity in Australia.